Compound interest: the eighth wonder of the world

Setting up a pharmaceuticals trust in the mid-1990s taught Max King the power of compounding

Investors are regularly reminded that compound returns are the eighth wonder of the world. But you don’t understand quite what that means until you are on the receiving end of them. I only fully appreciated the truth of the saying after investing in Finsbury Worldwide Pharmaceutical Trust, now the Worldwide Healthcare Trust, from its inception in early 1995.

I was the lead fund manager at Finsbury Asset Management, which I had joined in 1987 with the objective of turning four small investment trusts into successful UK-focused funds suitable for retail investors. 

Venturing abroad

By 1994, that process was well underway and our thoughts turned to launching a new trust. It is easy to forget how domestically-orientated most investors, even professional ones, were in those days, though with the FTSE 100 index producing compound capital returns, on trend, of 10% per annum, investing internationally wasn’t the necessity it now is. 

International funds were divided on geographic lines, which meant there was little comparison between companies in the same sector operating in the same global marketplace but listed on different national exchanges.

The sector that was most obviously crying out for an international approach was pharmaceuticals. The FTSE 100 contained four pharma stocks – Glaxo, SmithKlineBeecham, Wellcome and Zeneca – and there were also several smaller firms. 

However, the largest stock, Glaxo, only ranked number five in the world, even though it had grown its sales at a compound rate of 20% for ten years. Given the long-term growth potential of the healthcare sector, as obvious then as it is now, there was a compelling case for a global fund able to cross national boundaries but with access to specialist scientific knowledge.

Fortunately, my colleagues, William Salomon and Tony Townsend, knew just where to go. Mehta and Isaly was a New York-based brokerage firm specialising in pharmaceuticals. It covered over 300 companies, had successfully managed a US fund for five years and was enthusiastic about a sector that, following the failure of the Clinton healthcare reforms, was valued at a historically low level. It agreed to partner with us in the launch of a new investment trust.

The launch was not a success, raising just £14m. About £10m of that came, as promised in advance, from Equitable Life, while a couple of other investors put up seven figure amounts. Among the smaller investors was our internal pension fund, including 10,000 shares at £1 each from me. 

Despite their misgivings, the Stock Exchange permitted the listing to proceed. Since Sam Isaly was not authorised in the UK, he could only be an investment adviser. So, for the first two years, I was the official fund manager, a task that involved placing the orders which he “advised”. He was rather put out when I asked the reasons for his instructions but understood when I explained that I might be accountable for them and wanted to be able to field questions from investors without bothering him.

Small beginnings 

The trust returned around 40% in the first year, on the back of which we managed to raise another £40m. Many investors saw a London-listed trust with an overwhelmingly international portfolio as a way to cheat on the UK constraint they were under. Since then, the number of shares in issue has grown moderately but the share price multiplied again and again. 

Finsbury Asset Management was sold and I left, but rather than sell or cut my holding, I added to it. The most I paid was £5. Mehta and Isaly broke up; Isaly formed OrbiMed, a healthcare investment group, and it became the formal manager. The remit was broadened and the trust renamed. A few years ago, Isaly stepped back from OrbiMed but the trust has continued to prosper. Today’s share price close to £35 represents a compound return, excluding dividends, of 15% per annum. 

What are the lessons from this story? Small beginnings don’t preclude big successes. Trusts needn’t be prolific share issuers to grow big. Long-term continuity of management and style is vital. And if you find an area offering secure long-term growth with expert management, stick to it like glue. As Warren Buffett advised, “lethargy bordering on sloth should remain the cornerstone of an investment style”.

Recommended

Why investment trusts are the connoisseur’s choice of fund
Investment trusts

Why investment trusts are the connoisseur’s choice of fund

Investment trusts have justified their reputation as the best type of collective investment in 2020, says Jonathan Davis.
7 Dec 2020
Why investors should take investment trusts up on their free lunches
Investment trusts

Why investors should take investment trusts up on their free lunches

Investment trusts are brilliant, says Merryn Somerset Webb. Perhaps the most brilliant thing of all about them is the fact that investors can meet and…
16 Nov 2020
If you think now is a good time to buy, look at these investment trusts
Investment trusts

If you think now is a good time to buy, look at these investment trusts

With the latest market slides, an awful lot of assets are beginning to look very cheap indeed. If you are thinking of buying, Merryn Somerset Webb has…
10 Mar 2020
How to build a properly diversified investment trust portfolio
Sponsored

How to build a properly diversified investment trust portfolio

Max King explains how to build a well diversified portfolio using one of our favourite tools – investment trusts.
25 Feb 2020

Most Popular

Bitcoin does consume a lot of energy – but here’s why it’s worth it
Bitcoin

Bitcoin does consume a lot of energy – but here’s why it’s worth it

Some people question bitcoin’s legitimacy because it uses huge amounts of electricity to maintain its network. But that’s not a failing, says Dominic …
27 Jan 2021
Joe Biden’s spending spree will lift American spirits and markets – but it comes with a sting in the tail
US stockmarkets

Joe Biden’s spending spree will lift American spirits and markets – but it comes with a sting in the tail

New US president Joe Biden is planning to throw trillions of dollars in stimulus at his country’s economy. Markets will love that. But it comes with a…
25 Jan 2021
Think Tesla is a bubble? This might be the best way to bet on it bursting
Oil

Think Tesla is a bubble? This might be the best way to bet on it bursting

The huge rise in Tesla’s share price means that, by market value, it’s now the sixth-largest company in the US and and the world’s biggest car-maker. …
25 Jan 2021